Investor Summary

Parkinson’s disease (PD) affects over 8.5 million people worldwide, with motor symptoms typically emerging only after significant dopaminergic neuron loss. Yet oculomotor changes appear years earlier, offering a critical window for early intervention.

At O’VISTA, we’ve validated that subtle eye-movement anomalies—such as hypometric saccades, impaired smooth pursuit, reduced blink rate, and abnormal antisaccade control—serve as quantifiable, non-invasive biomarkers of early Parkinsonian pathology. These signals reflect dysfunction in basal ganglia–frontal circuits long before tremor or rigidity become clinically evident.

Our platform leverages AI-driven eye tracking and proprietary hardware to capture these signals in under five minutes—translating complex oculomotor dynamics into standardized, interpretable risk profiles. Unlike costly DaTscans or subjective clinical exams, O’VISTA delivers a scalable, low-cost, and repeatable triage tool for neurologists, movement disorder clinics, and even primary care networks.

We are prioritizing initial deployment in the Gulf Cooperation Council (GCC) and Middle East region, where:

• Aging populations are driving rising PD prevalence
• Healthcare systems are digitizing rapidly with strong innovation incentives
• Regulatory pathways for AI-enabled neurological screening are more agile than in the West

This strategic beachhead enables real-world validation, revenue generation, and partnership development—with minimal bureaucratic delay. Success here de-risks our path to Europe, Canada, the U.S., and Australia, where PD diagnostic markets are mature but fragmented, and where our GDPR/HIPAA-ready architecture ensures seamless compliance.

O’VISTA does not diagnose Parkinson’s—but it flags at-risk individuals for timely specialist referral, enabling earlier neuroprotective strategies, lifestyle interventions, and clinical trial enrollment. In a world where “time is neurons,” we offer the first scalable window into pre-motor Parkinson’s—starting in the Gulf, scaling worldwide.